Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002681 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
A Phase 1 study, sponsored by Roger Williams Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00002681 is a Phase 1 study that has completed, run by Roger Williams Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT00002681, a Phase 1 study, has completed, sponsored by Roger Williams Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia or lymphoma cells. Combining these two therapies may be an effective treatment for leukemia and lymphoma. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy plus interleukin-2 in treating patients who have leukemia or lymphoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL daclizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1995-07 |
| Est. Completion | 2003-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002681
The ClinicalTrials.gov registry entry for NCT00002681 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roger Williams Medical Center, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00002681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002681 about?
NCT00002681 is a clinical study titled "Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia or lymphoma cells. Combining these two therapies may be an effective trea...
What is the current status of trial NCT00002681?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 1995-07. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00002681?
The interventions under investigation include: aldesleukin (BIOLOGICAL), daclizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002681?
This trial is sponsored by Roger Williams Medical Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.